<![CDATA[NOVO — Februar 2026]]>Vedr recepttal på pillen så tales der om toppen af isbjerget, har vi nogen idé om hvor stor det reelle tal er? er det 2-3-4-5x det tal vi ser offentliggjort?

]]>https://dev.proinvestor.com/forum/topic/400330/novo-februar-2026RSS for NodeSat, 06 Jun 2026 06:06:11 GMTSun, 01 Feb 2026 14:46:13 GMT60<![CDATA[Reply to NOVO — Februar 2026 on Sat, 28 Feb 2026 15:12:26 GMT]]>(fort.) “Even with these rather conservative assumptions, Novo Nordisk seems to currently be undervalued by up to 60%.” Tror der er fri adgang til artiklen…

]]>https://dev.proinvestor.com/forum/post/7989527https://dev.proinvestor.com/forum/post/7989527Sat, 28 Feb 2026 15:12:26 GMT<![CDATA[Reply to NOVO — Februar 2026 on Sat, 28 Feb 2026 15:10:38 GMT]]>Seeking Alfa artikel - l https://seekingalpha.com/article/4876511-eli-lilly-vs-novo-nordisk-the-valuation-gap-is-unreasonable

]]>https://dev.proinvestor.com/forum/post/7989528https://dev.proinvestor.com/forum/post/7989528Sat, 28 Feb 2026 15:10:38 GMT<![CDATA[Reply to NOVO — Februar 2026 on Sat, 28 Feb 2026 13:17:35 GMT]]>okay

]]>https://dev.proinvestor.com/forum/post/7989525https://dev.proinvestor.com/forum/post/7989525Sat, 28 Feb 2026 13:17:35 GMT<![CDATA[Reply to NOVO — Februar 2026 on Sat, 28 Feb 2026 12:59:38 GMT]]>Nope - jeg snyder mig med gratis, jeg kan ikke en gang læse artiklen, kun overskriften.

]]>https://dev.proinvestor.com/forum/post/7989524https://dev.proinvestor.com/forum/post/7989524Sat, 28 Feb 2026 12:59:38 GMT<![CDATA[Reply to NOVO — Februar 2026 on Sat, 28 Feb 2026 12:56:00 GMT]]>Har du et link bikube?

]]>https://dev.proinvestor.com/forum/post/7989526https://dev.proinvestor.com/forum/post/7989526Sat, 28 Feb 2026 12:56:00 GMT<![CDATA[Reply to NOVO — Februar 2026 on Sat, 28 Feb 2026 10:30:08 GMT]]>Seeking Alfa mener: Eli Lilly Vs Novo the valuation gap is unreasonable. Det kan jeg da kun give ham ret i.

]]>https://dev.proinvestor.com/forum/post/7989520https://dev.proinvestor.com/forum/post/7989520Sat, 28 Feb 2026 10:30:08 GMT<![CDATA[Reply to NOVO — Februar 2026 on Sat, 28 Feb 2026 08:17:00 GMT]]>Walgreens debuts virtual weight management clinic with access to GLP-1 meds https://www.fiercehealthcare.com/health-tech/walgreens-debuts-virtual-weight-management-clinic-access-glp-1-meds?_gl=1*1t145on*_gcl_au*MTE2MTI4NzAyLjE3NzE5NjE1NTM.*_ga*MTAzNTI1NzA2NC4xNzcxOTYxNTQz*_ga_KG49J84SR4*czE3NzIyNjE1MjYkbzckZzEkdDE3NzIyNjE1MzQkajUyJGwwJGgw

]]>https://dev.proinvestor.com/forum/post/7989519https://dev.proinvestor.com/forum/post/7989519Sat, 28 Feb 2026 08:17:00 GMT<![CDATA[Reply to NOVO — Februar 2026 on Sat, 28 Feb 2026 07:18:02 GMT]]>Lillys Orfoglipron 10. april? https://proinvestor.com/boards/131357

]]>https://dev.proinvestor.com/forum/post/7989517https://dev.proinvestor.com/forum/post/7989517Sat, 28 Feb 2026 07:18:02 GMT<![CDATA[Reply to NOVO — Februar 2026 on Sat, 28 Feb 2026 06:21:23 GMT]]>Data fra Wegovy Pill Trx viser: 36,1% af patienterne havde aldrig taget GLP-1-medicin før. 21,1% var skiftet fra en injicerbar version til Wegovy-pille, 15,8% var skiftet fra Eli Lillys injicerbare Zepbound.
https://www.biospace.com/business/oral-wegovy-brings-in-thousands-of-new-glp-1-patients

]]>https://dev.proinvestor.com/forum/post/7989521https://dev.proinvestor.com/forum/post/7989521Sat, 28 Feb 2026 06:21:23 GMT<![CDATA[Reply to NOVO — Februar 2026 on Fri, 27 Feb 2026 20:53:51 GMT]]>FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indicationsFDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916507&utm_medium=organic&utm_source=twitter&utm_campaign=2026-media-release&utm_content=nni-pediatric-growth-sci_inn

]]>https://dev.proinvestor.com/forum/post/7989522https://dev.proinvestor.com/forum/post/7989522Fri, 27 Feb 2026 20:53:51 GMT<![CDATA[Reply to NOVO — Februar 2026 on Fri, 27 Feb 2026 20:17:06 GMT]]>I denne episode af The Downsized gennemgår Christopher Durham Novo Nordisks seneste REDEFINE 4-studieresultater for CagriSema - en næste generations fedmebehandling, der gav et gennemsnitligt vægttab på 23 % over 84 uger.

Denne video udforsker, hvad resultaterne rent faktisk viste, hvorfor de er vigtige, og hvordan de afspejler et bredere skift i fedmebehandling. https://proinvestor.com/boards/131354/

]]>https://dev.proinvestor.com/forum/post/7989523https://dev.proinvestor.com/forum/post/7989523Fri, 27 Feb 2026 20:17:06 GMT<![CDATA[Reply to NOVO — Februar 2026 on Fri, 27 Feb 2026 18:28:50 GMT]]>On the pen om lovgivning omkring compounding https://www.youtube.com/watch?v=y9TKVjmIrf8

]]>https://dev.proinvestor.com/forum/post/7989516https://dev.proinvestor.com/forum/post/7989516Fri, 27 Feb 2026 18:28:50 GMT<![CDATA[Reply to NOVO — Februar 2026 on Fri, 27 Feb 2026 12:54:14 GMT]]>THE @US_FDA
OFFICIALLY REMOVES SUICIDAL BEHAVIOR/IDEATION AND DEPRESSION FROM LIST OF POSSIBLE SIDE EFFECTS FROM ENTIRE CLASS OF OBESITY GLP-1 MEDICATIONS.

]]>https://dev.proinvestor.com/forum/post/7989518https://dev.proinvestor.com/forum/post/7989518Fri, 27 Feb 2026 12:54:14 GMT<![CDATA[Reply to NOVO — Februar 2026 on Fri, 27 Feb 2026 12:52:36 GMT]]>ResearchPulse
@ResearchPulse1
·

Wegovy pill IQVIA data up with 17.2% over last week……

Wegovy pen + pill up with about 3% over last week.

Zepbound down about 9% vs last week.

Wegovy keeps gaining back market share

Last week included Presidents Day. A holiday. https://x.com/ResearchPulse1/status/2027378898938318870

]]>https://dev.proinvestor.com/forum/post/7989512https://dev.proinvestor.com/forum/post/7989512Fri, 27 Feb 2026 12:52:36 GMT<![CDATA[Reply to NOVO — Februar 2026 on Fri, 27 Feb 2026 11:21:38 GMT]]>Investseekers
@investseekers
·

$NVO has partnered with Abbott India to launch Extensior, a new Ozempic brand for the Indian type 2 diabetes market.

Management says the collaboration should expand acce
ss in a country with 100M+ people living with diabetes, expected to exceed 150M by 2050.

The move comes as semaglutide patents begin expiring in India, with generics from players like Dr. Reddy’s preparing to enter the market.

]]>https://dev.proinvestor.com/forum/post/7989510https://dev.proinvestor.com/forum/post/7989510Fri, 27 Feb 2026 11:21:38 GMT<![CDATA[Reply to NOVO — Februar 2026 on Fri, 27 Feb 2026 10:47:21 GMT]]>Jo og så er der endda 7,95 udbyttekroner på vej den 27.3 og et aktietilbagekøbsprogram. Lidt svært helt at forstå, men man må jo forholde sig til virkeligheden.

]]>https://dev.proinvestor.com/forum/post/7989515https://dev.proinvestor.com/forum/post/7989515Fri, 27 Feb 2026 10:47:21 GMT<![CDATA[Reply to NOVO — Februar 2026 on Fri, 27 Feb 2026 10:31:54 GMT]]>.. Er det ikke en klassisk kapitulation, vi er vidner til?

]]>https://dev.proinvestor.com/forum/post/7989511https://dev.proinvestor.com/forum/post/7989511Fri, 27 Feb 2026 10:31:54 GMT<![CDATA[Reply to NOVO — Februar 2026 on Fri, 27 Feb 2026 10:22:37 GMT]]>Jeg ser umiddelbart 2026 som et svært "transition-år", hvor pillen bygger momentum til stærkere vækst fra 2027 på flere markeder. Det bliver spændende at se om det bliver tilfældet. 🙂

]]>https://dev.proinvestor.com/forum/post/7989507https://dev.proinvestor.com/forum/post/7989507Fri, 27 Feb 2026 10:22:37 GMT<![CDATA[Reply to NOVO — Februar 2026 on Fri, 27 Feb 2026 10:15:55 GMT]]>Indtil videre er salget af Wegovy-pillen en positiv overraskelse her tidligt i 2026 og kan måske hjælpe med at afbøde det samlede fald i revenue en smule. Jeg har ingen forventninger om at salget kan vende hele Novos revenue-trend alene i år – primært pga. priskrigen i USA. Desværre kan jeg se, at flere skribenter på de sociale aktiemedier nu tror, at pillesalget kan give grundlag for en større opjustering her 2026. Link til ugekommentaren: https://proinvestor.com/boards/131344/

]]>https://dev.proinvestor.com/forum/post/7989514https://dev.proinvestor.com/forum/post/7989514Fri, 27 Feb 2026 10:15:55 GMT<![CDATA[Reply to NOVO — Februar 2026 on Fri, 27 Feb 2026 10:00:56 GMT]]>Jeg kan ikke finde tal udover de 456 som Stockbull omtaler. Tallet har jeg dog set div kommentatorer/analytikere gentage. Jeg selv havde det i tankerne i går, da jeg i min ugekommentar fortalte om forventningerne til salget af Wegowy-pillen i 2026.

]]>https://dev.proinvestor.com/forum/post/7989506https://dev.proinvestor.com/forum/post/7989506Fri, 27 Feb 2026 10:00:56 GMT<![CDATA[Reply to NOVO — Februar 2026 on Fri, 27 Feb 2026 09:34:37 GMT]]>Vi skal bruge en koncensus tal fra mange + 20 analytikere

]]>https://dev.proinvestor.com/forum/post/7989505https://dev.proinvestor.com/forum/post/7989505Fri, 27 Feb 2026 09:34:37 GMT<![CDATA[Reply to NOVO — Februar 2026 on Fri, 27 Feb 2026 09:33:34 GMT]]>Tror ikke en bred konsensus (f.eks. fra 15–20 analytikere) - de 456 er visk kun fra
GlobalData (en enkelt kilde, nævnt i Pharmaceutical Technology-artikel fra jan 2026).

]]>https://dev.proinvestor.com/forum/post/7989508https://dev.proinvestor.com/forum/post/7989508Fri, 27 Feb 2026 09:33:34 GMT<![CDATA[Reply to NOVO — Februar 2026 on Fri, 27 Feb 2026 09:29:12 GMT]]>Godt set af prisen er pr. måned :-). Men uanset hvad vil de vel komme over analytikers estimat i midten af året. Hvis stigningen holder kan man vel regne med 1. mio. kunder i gennemsnittet i ultimo hvilket vil give en månedlig gennemsnitlig indtjening på små $200 mio. om måneden.

]]>https://dev.proinvestor.com/forum/post/7989503https://dev.proinvestor.com/forum/post/7989503Fri, 27 Feb 2026 09:29:12 GMT<![CDATA[Reply to NOVO — Februar 2026 on Fri, 27 Feb 2026 09:29:00 GMT]]>Så en opjustering efter Q1 og et forbedret Q2 i.f.t Q1 vil sparke kursen over 300 igen.

]]>https://dev.proinvestor.com/forum/post/7989502https://dev.proinvestor.com/forum/post/7989502Fri, 27 Feb 2026 09:29:00 GMT